Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Prostate cancer
Trial Type:  Prevention
Trial Status:  Closed
Sponsor of Trial:  NCI
Results 1-25 of 28 for your search:
Start Over
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Phase: Phase III
Type: Prevention
Status: Closed
Age: 55 and over (50 and over for African Americans)
Sponsor: NCI, Other
Protocol IDs: CDR0000068277, S0000, U10CA037429, SWOG-S0000, CAN-NCIC-S0000, CALGB-S0000, ECOG-S0000, NCCAM, NCI-P00-0172, NCT00006392
Phase III Randomized Study of Isoflavones in Reducing Risk Factors in Patients With Stage I or II Prostate Cancer
Phase: Phase III
Type: Prevention
Status: Completed
Age: 50 to 80
Sponsor: NCI
Protocol IDs: MCC-0002, NCI-4031, NCI-P01-0195, NCT00027950
S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate
Phase: Phase III
Type: Prevention
Status: Completed
Age: 40 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069210, U10CA037429, S9917, CALGB-70004, NCI-P02-0203, SWOG-S9917, ECOG-SWOG-S9917, NCT00030901
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Finasteride (Proscar) for the Chemoprevention of Prostate Cancer
Phase: Phase III
Type: Prevention
Status: Completed
Age: 55 and over
Sponsor: NCI
Protocol IDs: SWOG-9217, PCPT-1, NCI-P93-0049
Selenium in Preventing Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: Under 80
Sponsor: NCI, Other
Protocol IDs: 01-0506-01, R01CA077789, P30CA023074, UARIZ-99-0045-01,, 99-0045-01, NCT00978718
Phase II Study of Fenretinide Prior to Prostatectomy for Prostate Cancer (Summary Last Modified 01/99)
Phase: Phase II
Type: Prevention
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: UAB-9431, NCI-P97-0103
Phase II Study of Fenretinide versus Finasteride versus Placebo in Patients with Localized Prostate Cancer (Summary Last Modified 11/97)
Phase: Phase II
Type: Prevention
Status: Closed
Age: 40 to 75
Sponsor: NCI
Protocol IDs: BCM-H2533, NCI-P97-0107
Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer
Phase: Phase II
Type: Prevention
Status: Closed
Age: 35 to 70
Sponsor: NCI, Other
Protocol IDs: CDR0000068110, UCIRVINE-97-18, UCIRVINE-U01-CA-81886-01, NCI-P00-0164, NCT00006101
Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: PCI-00-105, CDR0000068708, PCI-N01-CN-75018, NCI-P01-0181, NCT00020735
Phase II Pilot Randomized Study of Selenium Versus Observation Only Before Radical Prostatectomy in Patients With Primary Adenocarcinoma of the Prostate
Phase: Phase II
Type: Prevention, Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: SWOG-S9812, NCI-P01-0182
Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000353197, P30CA022453, WSU-C-2418, NCT00078923
Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia
Phase: Phase II
Type: Prevention
Status: Closed
Age: 30 to 80
Sponsor: NCI, Other
Protocol IDs: MCC-15008, R01 CA12060-01A1, NCT00596011
Doxercalciferol Before Surgery in Treating Localized Prostate Cancer
Phase: Phase II
Type: Prevention, Treatment
Status: Closed
Age: 21 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068813, P30CA014520, WCCC-CO-99802, NCI-N01-CN-95130, WCCC-CO-2000169, NCI-P01-0188, NCT00022412
Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00451, UWI09-14-01, CDR0000698228, CO-10805, N01CN35153, P30CA014520, NCT01325311
Phase I Randomized Study of Genistein for Prevention of Cancer in Patients With No History of Cancer or With Asymptomatic Early Prostate Cancer or Other Malignancy
Phase: Phase I
Type: Prevention, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-98-C-0099B
Lycopene in Healthy Male Participants
Phase: Phase I
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 18 to 55
Sponsor: NCI
Protocol IDs: NCI-2012-02709, UIC-2006-0853, CDR0000536181, N01CN85081, N01-CN85081-4, NCT00450957
Vitamin E Supplements in Preventing Cancer in Patients at Risk of Prostate Cancer or Who Have Prostate Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 120802, P30CA072720, CDR0000639070, CINJ-120802, NCT00895115
Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants
Phase: Phase I
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 40 to 80
Sponsor: NCI
Protocol IDs: NCI-2012-00085, CDR0000717828, I 182210, NWU09-4-03, P30CA060553, N01CN35157, NU-NWU09-4-03, NCT01497431
Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate
Phase: No phase specified
Type: Prevention
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067929, NCCTG-959257, MAYO-959257, MAYO-IRB-921-97, NCI-P00-0156, NCT00006214
Fish Oil and Green Tea Extract in Preventing Prostate Cancer in Patients Who Are at Risk for Developing Prostate Cancer
Phase: No phase specified
Type: Prevention
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000443617, P30CA069533, OHSU-CI-CPC-04131-LX, VAMC-04-0303/ M1016, DOD-W81XWH-04-1-0296, OHSU-1117, KPNW-NW-05SLIEB-01, VAMC-04-0303, DOD-A-12538, OHSU-KPNW-NW-05SLIEB-01, NCT00253643
Start Over